Pelage Pharmaceuticals
Pelage Pharmaceuticals develops regenerative medicine therapies focused on treating hair loss by reactivating dormant hair follicle stem cells. Its lead candidate, PP405, is a topical small molecule designed to modulate metabolic signaling in hair follicles so that inactive stem cells reenter the growth cycle. Pelage positions PP405 as a non-hormonal, non-invasive treatment intended to work across different genders, skin types, and hair types. The company is currently conducting Phase 2a clinical trials in androgenetic alopecia and aims to expand into other hair loss conditions. Its scientific team draws on work in stem cell biology and metabolic regulation and publishes its translational and clinical data in peer-reviewed channels.
Domain
pelagepharma.com
Country
United StatesIndustry
Health CareEmployees
1-10
Last Funding
$120.0M
Founded
2017
Tech Stack (19 technologies)
Frequently Asked Questions
What technologies does Pelage Pharmaceuticals use?+
Pelage Pharmaceuticals uses 19 technologies including Elementor, Google Analytics, Google Tag Manager.
What industry is Pelage Pharmaceuticals in?+
Pelage Pharmaceuticals operates in the Health Care industry.
Where is Pelage Pharmaceuticals based?+
Pelage Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026